Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. COCP
stocks logo

COCP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.180
-43.75%
--
--
-0.200
-13.04%
--
--
-0.195
-2.5%
Estimates Revision
The market is revising No Change the revenue expectations for Cocrystal Pharma, Inc. (COCP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -29.83%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-29.83%
In Past 3 Month
Wall Street analysts forecast COCP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCP is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast COCP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCP is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.035
sliders
Low
10.00
Averages
10.00
High
10.00
Current: 1.035
sliders
Low
10.00
Averages
10.00
High
10.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$7 -> $6
2025-06-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$7 -> $6
2025-06-21
downgrade
Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$7
2025-01-22
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$7
2025-01-22
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cocrystal Pharma Inc (COCP.O) is -1.34, compared to its 5-year average forward P/E of -2.70. For a more detailed relative valuation and DCF analysis to assess Cocrystal Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.70
Current PE
-1.34
Overvalued PE
0.32
Undervalued PE
-5.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.52
Undervalued EV/EBITDA
-0.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.18
Current PS
0.00
Overvalued PS
41.94
Undervalued PS
-7.58
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

COCP News & Events

Events Timeline

(ET)
2025-11-14
08:06:36
Cocrystal Pharma announces Q3 earnings per share of 19 cents, compared to a loss of 49 cents in the previous year.
select
2025-10-30 (ET)
2025-10-30
08:23:04
Cocrystal Pharma finalizes $1.03 million private placement deal
select
2025-10-27 (ET)
2025-10-27
08:18:08
Cocrystal Pharma awarded NIH SBIR grant to further develop influenza inhibitor initiative
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-01Globenewswire
Cocrystal Pharma to Present Clinical Progress at NobleCon 21
  • Conference Presentation: Cocrystal Pharma's CFO and co-CEO James Martin will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025, showcasing the latest advancements in antiviral treatments.
  • Investor Participation: The conference invites interested investors and guests to attend at a discounted rate, aiming to increase visibility and engagement within the small and micro-cap market.
  • Webcast Availability: A video of Cocrystal's presentation will be available on December 4 and archived for 90 days on the company's website, ensuring that investors unable to attend live can access critical information.
  • Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis, leveraging unique structure-based technologies and Nobel Prize-winning expertise to create first-in-class antiviral drugs.
[object Object]
Preview
1.0
10-02Newsfilter
Cocrystal Pharma to Showcase at Noble Capital Markets Virtual Equity Conference for Emerging Growth Companies

  • Cocrystal Pharma Presentation: Cocrystal Pharma's CFO and co-CEO, James Martin, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025, followed by a Q&A session.

  • Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases like influenza and COVID, utilizing unique technologies and expertise.

[object Object]
Preview
8.5
09-12SeekingAlpha
Cocrystal Pharma reveals direct offering of up to $13 million.

  • Stock Offering Details: Cocrystal Pharma has announced a registered direct offering of 2.76 million shares at $1.70 per share, alongside a private placement of unregistered warrants for up to 5.53 million shares at an exercise price of $1.50.

  • Financial Projections: The company expects to raise approximately $4.7 million from the offering, with potential additional proceeds of about $8.3 million if the warrants are fully exercised.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cocrystal Pharma Inc (COCP) stock price today?

The current price of COCP is 1.035 USD — it has decreased -0.48 % in the last trading day.

arrow icon

What is Cocrystal Pharma Inc (COCP)'s business?

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

arrow icon

What is the price predicton of COCP Stock?

Wall Street analysts forecast COCP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCP is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cocrystal Pharma Inc (COCP)'s revenue for the last quarter?

Cocrystal Pharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Cocrystal Pharma Inc (COCP)'s earnings per share (EPS) for the last quarter?

Cocrystal Pharma Inc. EPS for the last quarter amounts to -0.19 USD, decreased -61.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cocrystal Pharma Inc (COCP)'s fundamentals?

The market is revising No Change the revenue expectations for Cocrystal Pharma, Inc. (COCP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -29.83%.
arrow icon

How many employees does Cocrystal Pharma Inc (COCP). have?

Cocrystal Pharma Inc (COCP) has 11 emplpoyees as of December 05 2025.

arrow icon

What is Cocrystal Pharma Inc (COCP) market cap?

Today COCP has the market capitalization of 14.27M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free